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Abstract
Background: Although antihistamines and topical corticosteroids are used in combination to treat allergic rhinitis,
their additive effect has not been yet demonstrated. The aim was investigate the antiinflammatory additive effect
of mometasone and desloratadine on cytokine and sICAM-1 secretion by epithelial cells, and on eosinophil survival
stimulated by human epithelial cells secretions from nasal mucosa and polyps.
Methods: Epithelial cells obtained from nasal mucosa or polyps were stimulated with 10% fetal bovine serum in
presence of mometasone (10-11M-10-5M) with/without desloratadine (10-5M). Cytokine and sICAM-1 concentrations
in supernatants were measured by ELISA. Peripheral blood eosinophils were incubated during 4 days with
epithelial cell secretions with (10-11M-10-5M) and/or desloratadine (10-5M) and survival assessed by Trypan blue.
Results are expressed as percentage (mean ± SEM) compared to control.
Results: Fetal bovine serum stimulated IL-6, IL-8, GM-CSF and sICAM-1 secretion. In mucosa and polyp epithelial
cells, mometasone inhibited this induced secretion while desloratadine inhibited IL-6 and IL-8. The combination of
10-5M desloratadine and 10-9M mometasone reduced IL-6 secretion (48 ± 11%, p < 0.05) greater extent than
mometasone alone (68 ± 10%) compared to control (100%). Epithelial cell secretions induced eosinophil survival
from day 1 to 4, this effect being inhibited by mometasone. At day 4, the combination of mometasone (10-11M)
and desloratadine (10-5M) provoked an increased inhibition of eosinophil survival induced by cell secretions (27 ±
5%, p < 0.01) than mometasone (44 ± 7%) or desloratadine (46 ± 7%) alone.
Conclusions: These results suggest that the combination of desloratadine and mometasone furoate have a greater
antinflammatory effect in an in vitro model of eosinophil inflammation than those drugs administered alone.
Background
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS)
with/without nasal polyposis (NP) are diseases charac-
terized by upper airway mucosal inflammation with ele-
vated levels of pro-inflammatory cytokines and
eosinophil infiltration [1-3]. Concentrations of IL-1b,
IL-4, and IL-5 are increased in nasal secretions from
patients with AR, while other cytokines such as IL-6,
IL-8, eotaxin, tumor necrosis factor-alpha (TNF-a),
Interferon-g, granulocyte-macrophage colony-stimulating
factor (GM-CSF), vascular endothelial growth factor
(VEGF) and transforming growth factor-b (TGF-b),
as well as chemokines such as eotaxin and RANTES,
are also increased in patients suffering from CRS with
NP [4-6].
The increased level of pro-inflammatory mediators plays
a role in the eosinophil infiltration of nasal mucosa. Some
of these cytokines and other mediators such as platelet-
activating factor (PAF), adhesion molecules and cysteinyl
leukotrienes induce eosinophilopoeisis, cell recruitment
from peripheral blood to the site of inflammation, and
increase eosinophil survival and activation [7-12]. In fact,
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epithelial cells may contribute to eosinophilic inflamma-
tion through the release of GM-CSF, IL-8 and TNF-a [7].
The first line treatment of upper airway inflammation
includes corticosteroids and antihistamines [2]. Corti-
costeroids such as mometasone furoate (MF) and others
have been shown to be effective in the treatment of
allergic rhinitis and rhinosinusitis [13,14]. Among
others, the antiinflammatory effect of costicosteroids
includes the inhibition of cytokine secretion from
epithelial cells and the reduction of the eosinophil survi-
val [7,11,15,16]. Specifically, it has been reported that
MF inhibits the synthesis of several cytokines in both
the respiratory cell line A549 [17] and human keratino-
cytes [18], but the effect on upper airway epithelial cells
has not been yet reported. In addition, it has been
demonstrated that MF induces eosinophil apoptosis [19]
and reduces their number in NM biopsies [20], suggest-
ing that, like other glucocorticoids, MF is capable to
directly act on these cells. On the other hand, antihista-
mines such as desloratadine (DL) have shown to be
effective in the treatment of allergic rhinitis and asthma
[21,22], including some anti-inflammatory functions.
In fact, DL inhibits cytokine secretion from NM and NP
epithelial cells, basophils, and mast cells [12,23,24].
Although current ARIA Guidelines recommend the
combination of antihistamines and topical corticoster-
oids for the treatment of allergic rhinitis [25], few stu-
dies have been conducted to demonstrate the efficacy of
combined treatment on upper airway inflammation, and
the benefits compared with antihistamine or corticoster-
oid monotherapy are still not clear. In fact, some studies
with patients suffering from AR demonstrated no addi-
tional benefit when MF where used in combination with
loratadine [26], while others found significant improve-
ment when using the combination of flunisolide with
loratadine [27], fluticasone with cetirizine [28] and MF
with DL [29]. However, no study has yet reported the
additive anti-inflammatory effect of antihistamines and
corticosteriods.
The present study, carried out in on in vitro validated
model of cultured upper-airway epithelial cells and per-
ipheral blood eosinophils [7,11,12,15,16], was designed
to investigate the additive anti-inflammatory effects of
DL and MF on proinflammatory cytokines and soluble
intercellular adhesion molecule (sICAM)-1 secretion
from both NM and NP epithelial cell cultures as well as
on eosinophil survival primed by secretions from both
NM and NP cultured epithelial cells.
Methods
Materials
Ham’s F-12 and RPMI 1640 medium was purchased
from Bio Whittaker Europe (Verviers, Belgium); 24-well
culture plates from Costar (Cultek SL, Madrid, Spain);
desloratadine and mometasone furoate from Schering
Plough (New Jersey, USA); penicillin-streptomycin, fetal
bovine serum (FBS) from Invitrogen Corporation (Pais-
ley, Scotland, UK); and amphotericin B from Squibb
(Esplugues de Llobregat, Catalonia, Spain). Hydrocorti-
sone, N-formyl-methionyl-leucyl-phenylalanine, human
transferrin, bovine insulin, 3,3’,5-triiodo-l-tyrosine
sodium salt, protease type XIV, light mineral oil, gluta-
mine, trypan blue and dimethyl sulfoxide (DMSO) were
obtained from Sigma-Aldrich Co. (Madrid, Spain);
endothelial cell growth supplement and epidermal
growth factor were supplied by Collaborative Research
Inc. (Bedfort, MA, USA); cytokine ELISA kits from
Amersham Biosciences Europe (Cerdanyola, Spain) and
Diaclone (Stamford, CT, USA); and rat tail collagen type
I from Upstate (Lake Placid, NY, USA).
Study population
Nasal mucosa specimens were obtained from 9 patients
(7 men, 2 women), ranging in age from 23 to 62 years
(45.5 ± 5.2 yr), who underwent nasal corrective surgery
for septal dismorphy, turbinate hypertrophy, or both.
Skin-prick test was positive in two patients (22.2%).
None of the patients were receiving topical or systemic
glucocorticoid or antihistamine treatment on the 4 week
prior the surgery.
Nasal polyp specimens were obtained from 9 patients
(5 men, 4 women), ranging from 34 to 83 years (56.9 ±
5.2 yr), underwent endoscopic sinonasal surgery with
nasal polypectomy. Skin-prick test was positive in two
patients (22.2%). Three patients (33.3%) also had conco-
mitant asthma and 6 patients (66.6%) were on regular
treatment with intranasal corticosteroids. None of them
had aspirin sensitivity.
None of the patients had had an upper airway infec-
tion the 2 weeks before surgery.
All patients gave informed consent to participate in
the study, which was approved by the Scientific and
Ethic’s Committee of our Institution.
Isolation of epithelial cells
Tissue specimens were placed in Ham’s F-12 medium
supplemented with penicillin (100 UI/ml), streptomycin
(100 μg/ml), amphotericin B (2 μg/ml), and immediately
transported to the laboratory. Epithelial cells from nasal
mucosa or polyps were isolated by protease digestion
using a technique previously reported [7,8,15,16]. Viabi-
lity of cells was assessed by trypan blue dye exclusion
using a hemocytometer. Cell population was character-
ized using smears obtained by cytocentrifugation
(500 rpm, 10 min) and stained with May-Grünwald-
Giemsa or with mouse monoclonal anti-cytoketarin
antibody using the immune-alkaline phosphatase
method [7,8,15]. After tissue protease digestion, cell
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viability was 91.8 ± 2.9% for NMs and 89.0 ± 2.9% for
NPs, and the percentage of epithelial cell purity was
98.9 ± 0.1% for NM and 92.3 ± 1.3% for NP specimens.
Culture of epithelial cells
Epithelial cell suspensions (105 cells/well) were placed
on 24-well plates coated with rat tail collagen type I in a
hormonally defined serum-free media: F-12 culture
medium (2 ml), antibiotics (penicillin, 100 UI/ml; strep-
tomycin, 100 μg/ml), amphotericin B (2 μg/ml), gluta-
mine (150 μg/ml), transferrin (5 μg/ml), insulin (5 μg/
ml), epidermal growth factor (25 ng/ml), endothelial cell
growth factor supplement (15 μg/ml), triiodothyronine
(200 pM) and hydrocortisone (100 nM). Epithelial cells
were cultured in 5% CO2 humidified atmosphere at
37°C, the culture media being changed every 2 days.
After cell culture, the percentage of epithelial cell purity
was 100% for both NM and NP cultures.
Generation of Human Epithelial Conditioned Media
(HECM). When epithelial cell cultures reached 80% con-
fluence, the hormonally defined serum-free media was
switched to RPMI-1640 media supplemented with antibio-
tics (penicillin, 100 UI/ml; streptomycin, 100 μg/ml),
amphotericin B (2 μg/ml), glutamine (150 μg/ml) and
HEPES buffer (25 nM). Since previous studies have shown
that non-stimulated epithelial cells produce low levels of
cytokines [7,15], cultured epithelial cells were incubated
with FBS at 10% in the presence or absence of different
concentrations of MF (from 10-11 to 10-5M) and/or DL
(10-5M) for 24 hours. After incubation, cell supernatants
(HECM) were harvested from cultures, centrifuged at
400 g (10 min, 25°C), sterilized through 0.22 μm filters,
and stored at -80°C until used. In order to avoid different
effects of FBS from different batches and sources, the
same manufacturing batch was used in all experiments.
Enzymo-Linked Immunoassays (ELISA) of cytokines and
sICAM-1
The concentrations of GM-CSF, IL-6, IL-8, and sICAM-
1 were measured in HECM from NM and NP cultured
epithelial cells using commercial ELISA kits. The assay
ranges were: 15.4 to 600 pg/ml for GM-CSF, 1.56 to
50 pg/ml for IL-6, 25 to 1000 pg/ml for IL-8, and 250
to 8000 pg/ml for sICAM-1. To verify that the sub-
stances used in the different experiments (MF, DL, FBS)
did not affect the ELISA results, wells containing either
culture media alone or media with the highest drug con-
centration used in the different protocols were com-
pared (n = 3). None of the substances showed any
intrinsic effect on the ELISA final values.
Isolation of eosinophils
Normodense eosinophils were obtained from 10 atopic
and non-atopic subjects with >3% in peripheral blood
eosinophils. None of the patients were receiving topical
or systemic glucocorticoid or antihistamine treatment
on the 4 week prior the blood extraction. All patients
gave informed consent to participate in the study, which
was approved by the Scientific and Ethic’s Committee of
our Institution. Eosinophils were obtained by a pre-
viously described method [8,9,12,16] using discontinu-
ous Percoll® gradients. Eosinophil viability and purity
(> 90%) were quantified by trypan blue dye exclusion
and May-Grünwald-Giemsa staining, respectively.
Assessment of Eosinophil survival
Eosinophils (2.5 × 105 cells/well) were incubated in
24-well tissue culture plates with RPMI (2 ml) in the
presence or absence of MF (from 10-11 to 10-5M) and/or
DL (10-5M) at 37°C for 1 hr before the addition of 10%
HECM from nasal mucosa (NM-HECM) or polyps (NP-
HECM). Eosinophil survival index was assessed at 24 hr
(day 1), 48 hr (day 2), 72 hr (day 3) and 96 hr (day 4) of
incubation by trypan blue dye exclusion. The eosinophil
survival index was calculated as follows: number of eosi-
nophils recovered × percentage of eosinophil viability/
number of eosinophils delivered on day 0. In order to
reduce the variability of HECM in all experiments, nasal
mucosa or nasal polyp HECM were created by mixing
cell supernatants from all NM or NP epithelial cell
cultures.
Because MF and DL were diluted in ethanol and
DMSO, respectively, and the HECM added to the eosi-
nophil cultures contained 10% FBS, we investigated the
effect of ethanol, DMSO and FBS on eosinophil survival.
Neither ethanol, DMSO nor FBS at the higher final con-
centration present in the culture media (0.1% ethanol
when MF was at 10-5M, 0.1% DMSO when DL was at
10-5M, and 1% FBS when HECM was at 10%) had a sig-
nificant effect on eosinophil survival (data not shown).
Statistical Analysis
Statistical evaluations were performed using the statisti-
cal software Microsoft SPSS 16.0. Results are expressed
as mean ± SEM (standard error of the mean). A non-
parametric test, Wilcoxon’s signed-rank test was used in
cytokine secretion experiments and U Mann-Whitney
test was used for statistical comparisons in eosinophil
survival experiments. P < 0.05 was considered statisti-
cally significant.
Results
Effect of FBS on cytokine and sICAM-1 secretion
In NM epithelial cell cultures (N = 9), FBS increased
the secretion of IL-6 (media: 254 ± 65 pg/ml; 10% FBS:
1697 ± 437 pg/ml; p < 0.05), IL-8 (media: 1504 ±
462 pg/ml; 10% FBS: 5186 ± 1132 pg/ml; p < 0.05), GM-
CSF (media: 159 ± 56 pg/ml; 10% FBS: 395 ± 115 pg/ml;
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p < 0.05) and sICAM-1 (media: 517 pg/ml ± 147 pg/ml;
10% FBS: 1606 ± 320 pg/ml; p < 0.05).
In NP epithelial cell cultures (N = 9), FBS increased
the secretion of IL-6 (media: 376 ± 207 pg/ml; 10% FBS:
2132 ± 779 pg/ml; p < 0.05), IL-8 (media: 1252 ± 836
pg/ml; 10% FBS: 4420 ± 2852 pg/ml; p < 0.05), GM-CSF
(media: 115 ± 23 pg/ml; 10% FBS: 393 ± 118 pg/ml; p <
0.05) and sICAM-1 (media: 498 ± 108 pg/ml; 10% FBS:
2111 ± 751 pg/ml; p < 0.05).
No significant differences were found in the concen-
tration of these cytokines and sICAM-1 between NM
and NP-HECM.
Effect of mometasone furoate on cytokine and sICAM-1
secretion
In both NM and NP polyp epithelial cell cultures, MF
significantly decreased the FBS-induced IL-6, IL-8 and
GM-CSF secretion in a dose-dependent manner. MF
also inhibited the sICAM-1 secretion in NM and NP
epithelial cell cultures, but not in a dose-response
manner. Compared to NM, MF effect was less potent
in NP cultures for the secretion of IL-6 and sICAM-1
(Figures 1 and 2).
Combined effect of mometasone furoate plus
desloratadine on cytokine and sICAM-1 secretion
In NM cultured epithelial cells (N = 9), and compared
to FBS treated cultures (100%), the combination of DL
at 10-5M and MF at 10-9M reduced the FBS-induced
IL-6 release (48 ± 11%) significantly higher than when
MF at 10-9M (68 ± 10%) was used alone (Figure 3) and
not significantly different from MF at 10-7M (32 ± 6%)
or DL at 10-5M (62 ± 13%). The inhibitory effect of DL
(10-5M) plus MF (10-11 to 10-7M) on IL-6 release in NP
epithelial cells were not significantly different when
compared to that of MF alone (data not shown).
In NP cultured epithelial cells (N = 9), and compared
to FBS treated cultures (100%), the combination of DL
at 10-5M and MF at 10-11M decreased significantly the
FBS-induced sICAM-1 secretion (68 ± 10%, p < 0.05),
whereas both drugs administered alone did not. The
inhibitory effect of DL (10-5M) plus MF (10-11 to 10-7M)
on IL-6 release in NM epithelial cells were not signifi-
cantly different when compared to that of MF alone
(data not shown).
The inhibitory effect of DL (10-5M) plus MF (10-11 to
10-7M) on IL-8 and GM-CSF release in both NM and
NP epithelial cells were not significantly different when
compared to that of MF alone (data not shown).
Effect of mometasone furoate on HECM-induced
eosinophil survival
HECM from both NM and NP significantly (p < 0.01)
induced eosinophil survival from day 1 to day 4
compared to media alone (N = 10). MF at 10-5M signifi-
cantly decreased the NM and NP-HECM-induced eosi-
nophil survival from day 1 to day 4 (Figure 4). At day 4,
MF had a significant dose-related inhibitory effect (from
10-5 to 10-11M) on both the NM and NP-HECM-
induced eosinophil survival (Figure 5).
Additive effect of mometasone furoate plus desloratadine
on eosinophil survival
There were no differences between MF and the combi-
nation with DL when studied NM and NP-HECM-
induced eosinophil survival at days 1 to 3. At day 4, the
combination of MF at 10-11M and DL at 10-5M caused
a significant decrease in NM-HECM-induced eosinophil
survival that was higher that when MF or DL where
used alone, and similar to the effect of MF at 10-7M
alone. When eosinophil survival was induced by NP-
HECM, the combination of MF at 10-11M and DL at
10-5M also caused a significant decrease in HECM-
induced eosinophil survival that was significantly higher
than DL alone but not for MF alone, although at ten-
dency was found (p = 0.06). This effect was also similar
to that from MF 10-7M (Figure 6).
Discussion
The main findings of our study are: 1st) fetal bovine
serum induced the secretion of IL-6, IL-8, GM-CSF,
and sICAM-1 by cultured epithelial cells from both
nasal mucosa and polyps; 2nd) in both nasal mucosa
and polyp epithelial cells, mometasone inhibited the
induced secretion of IL-6, IL-8, GM-CSF and sICAM-
1; 3rd) desloratadine weakly but significantly poten-
tiated the inhibitory effect of low concentrations of
mometasone (nanomolar) on IL-6 secretion from nasal
mucosa epithelial cells; 4th) epithelial cell secretions
from both nasal mucosa and nasal polyps induced
eosinophil survival; 5th) mometasone inhibited in a
dose-dependent manner the eosinophil survival
induced by both nasal mucosa and nasal polyp epithe-
lial secretions; and 6th) desloratadine weakly but sig-
nificantly potentiated the effect of low concentrations
of mometasone (picomolar) on decreasing eosinophil
survival, especially when epithelial secretions were
from nasal mucosa.
In the present study, we have shown that human nasal
mucosa and polyp epithelial cells increased the release
of IL-6, IL-8, GM-CSF, and sICAM-1 in response to
FBS. These findings confirm our previous studies which
show that cultured nasal epithelial cells from both
human nasal mucosa and nasal polyp express and
release GM-CSF, IL-1b, IL-6, IL-8 and TNF-a
[7,11,12,15,16,30]. Moreover, a recent study has reported
high concentrations of IL-6 in nasal tissue from patients
suffering from CRS with NP [6]
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In our in vitro model of eosinohil inflammation, MF
showed an inhibitory effect on FBS-induced IL-6, IL-8,
GM-CSF, and sICAM-1 secretion in both nasal mucosa
and polyp epithelial cell cultures. In fact, we have pre-
viously demonstrated that other corticosteroids, such as
beclometasone dipropionate fluticasone, triamcinolone
and budesonide, have a similar effect [11,15,16]. This
inhibitory effect suggests that these drugs, including MF
may decrease inflammation in the upper airways by
inhibiting pro-inflammatory cytokine release by epithe-
lial cells, and consequently, leading to a reduction in
inflammatory cell recruitment and activation promoted
by such cytokines. In support with our findings, it has
been reported that MF inhibit the cytokine-induced
GM-CSF expression in a respiratory cell line [17], the
LPS-induced IL-1, IL-6 and TNF-a expression in
murine blood cells [18] as well as the ICAM-1 expres-
sion in skin [31] and lung fibroblasts [32].
In the present study, DL inhibited IL-6 secretion from
both NM and NP epithelial cells. We realize that the
high concentrations of DL used in our study are signifi-
cantly higher than those found in blood or epithelial lin-
ing fluid during the treatment of patients. However,
since our research is a mechanistic study, our research
cannot be used as a guide for therapeutic indications. In
fact, previous studies have found similar results in rela-
tion to DL effect on pro-inflammatory mediators’ pro-
duction and secretion, not only in epithelial cells but
also in other cell types. On this regard, DL decreased
IL-6 and IL-8 secretion from basophilic cells (KU812)
and human mast cell line (HMC-1) [33], IL-4 and IL-13
from basophil-enriched suspension [24], and GM-CSF
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Figure 1 Effect of mometasone on IL-6 and IL-8 induced secretion from epithelial cells. Epithelial cells were incubated with 10% fetal
bovine serum (FBS) in presence of mometasone (MF) for 24 h. MF caused a dose-related inhibitory effect on FBS-induced IL-6 (A) and IL-8 (B)
release. Results expressed as mean ± SEM. Wilcoxon Signed Rank test was used for statistical comparison. *P < 0.05 and **P < 0.01 compared to
control; †P < 0.05 and ††P < 0.01 compared to 10% FBS. N = 9.
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secretion from HMC-1 cells [34] and airway epithelial
cells [12]. The inhibition of a wide range of cytokines
suggests that DL may play a role in modulating media-
tors associated with the airway inflammatory process.
When used in combination with the corticosteroid MF,
DL was able to increase the inhibitory effect caused by
MF alone on IL-6 secretion, and to inhibit IL-8 secretion
in a dose of MF that caused no significant effect on this
cytokine when administered alone. Thus, DL seems to
improve and potentiate MF effects on cytokine secretion
by nasal epithelial cells. However, this effect seems to be
present only at low but significant inhibitory doses of
MF. To some extent, these findings agree with clinical
trials in which it has been demonstrated improvements
in the sneezing [27], rhinorrhoea [27], total symptom
score [28], nasal itching [28] and total nasal symptom
score [29] when combining different corticosteroids
and antihistamines in the treatment of allergic and non-
allergic rhinitis.
In the present study, MF decreased the eosinophil survi-
val induced by epithelial secretions from both NM and
NP. In keeping with our results, it has been reported that
MF reduced the sputum eosinophilia in asthmatic patients
[35], decreased the number of eosinophils in nasal mucosa
biopsies [20] and induced apoptosis in eosinophil cultured
in vitro [19]. In addition, we found that DL reduced eosi-
nophil survival induced by epithelial secretions from nasal
mucosa, as previously reported [12].
When investigating the combined effect of MF plus
DL on eosinophil viability, an additive effect was found
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Figure 2 Effect of mometasone on GM-CSF and sICAM-1 induced secretion from epithelial cells. Epithelial cells were incubated with 10%
fetal bovine serum (FBS) in presence of mometasone (MF) for 24 h. MF caused a dose-related inhibitory effect on FBS-induced GM-CSF (A)
sICAM-1 (B) release. Results expressed as mean ± SEM. Wilcoxon Signed Rank test was used for statistical comparison. **P < 0.01 compared to
control; †P < 0.05 and ††P < 0.01 compared to 10% FBS. N = 9.
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on eosinophil survival induced by epithelial cell secre-
tions, since DL increased the inhibitory effect of
MF alone. In the same line, it has been reported that
loratadine improved the effect of a corticosteroid in the
treatment of non-allergic rhinitis with eosinophilia
decreasing eosinophil counts in nasal smears [27] and
nasal sneezing in seasonal allergic rhinitis [26].
Conclusions
In summary, the present study suggests that the combi-
nation of mometasone furoate and desloratadine dimin-
ish eosinophil inflammation in a greater extent than
those drugs administered alone, confirming a common
antiinflammatory mechanism for these kind of drugs.
However, further in vivo study must be performed to
clarify the clinical applications of the in vitro findings.
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Figure 3 Additive effect of mometasone and desloratadine on
interleukin-6 secretion from nasal mucosa epithelial cells. Nasal
mucosa epithelial cell were incubated with 10% fetal bovine serum
(FBS) in presence of mometasone (MF) with/without desloratadine
(DL). Additive effect was found when using MF at 10-9M plus DL
10-5M. Results expressed as mean ± SEM. Wilcoxon Signed Rank test
was used for statistical comparison. **P < 0.01 compared to control;
†P < 0.05 and ††P < 0.01 compared to 10% FBS. N = 9.
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Figure 4 Kinetics of human epithelial conditioned media
(HECM) and mometasone effect on eosinophil survival. HECM
at 10% (filled circles) from nasal mucosa and nasal polyps
significantly increased eosinophil survival compared to control
media (open circles) from day 1 to 4. Mometasone at 10-5 M (filled
triangles) inhibited the HECM-induced eosinophil survival at all time
points. Results expressed as mean ± SEM of eosinophil survival
index. Mann-Whitney U test was used for statistical comparison
**p < 0.01, HECM compared to control media; ††P < 0.01 MF
compared to HECM. N = 10.
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Figure 5 Mometasone effect on eosinophil survival at day 4.
Human epithelial conditioned media (HECM) at 10% (dark grey
bars) from nasal mucosa and nasal polyp induced eosinophil
survival. Mometasone (MF, light grey bars) caused a dose-related
inhibition of the induced eosinophil survival. Results expressed as
mean ± SEM of eosinophil survival index. Wilcoxon Signed Rank test
was used for statistical comparison. **p < 0.01, compared to control
media; †p < 0.05, ††p < 0.01, compared to HECM.
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Figure 6 Additive effect of mometasone and desloratadine on
eosinophil survival at day 4. Human epithelial conditioned media
(HECM) at 10% (dark grey bars) from nasal mucosa and nasal polyp
increased eosinophil survival compared. The combination of
mometasone (MF) at 10-11M and desloratadine (DL) at 10-5M
(striped bars) caused an inhibitory effect higher than MF (light grey
bars) or DL (white bars) alone, and similar to MF at 10-7M. This
additive effect was significant when eosinophil survival was induced
by nasal mucosa HECM. Results expressed as mean ± SEM of
eosinophil survival index. Wilcoxon Signed Rank test was used for
statistical comparison. **p < 0.01, compared to control media;
†p < 0.05, compared to HECM. N = 10.
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